Maybe they wanted nimo out of the equation since they both have an EGFR inhibitor and didn't want the other party to worry that they would be acquiring a like compound. Maybe they said we have a deal but you must sell NIMO first so that our co-marketer is not offended. Remember LLY bought IMCL and BMY sold interest to LLY keeping marketing rights to Cextuximab! Makes since both need more of a presence in RA and Hem. Is 4.5 too low for buyout? Could it go to higher? I don't see partnership since the revenue stream just went out the window! Some cash coming in is better than no cash coming in! If you had a partner lined up why sell nimo? I got a feeling it is buyout all the way!